The DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Open accessPublished version of a preprint
Abstract
KRAS is one of the most frequently mutated proto-oncogenes in human cancers. The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers. The consistency, frequency, and tumor specificity of these “neoantigens” make them attractive therapeutic targets. Recent data associate T cells that target mutated antigens with clinical immunotherapy responses in patients with metastatic melanoma, lung cancer, or cholangiocarcinoma. Using HLA-peptide prediction algorithms, we noted that HLA-A*11:01 could potentially present mutated KRAS variants. By immunizing HLA-A*11:01 transgenic mice, we generated murine T cells and subsequently isolated T-cell receptors (TCR) highly reactive to the mutated KRAS variants G12V and G12D. Peripheral blood lymphocytes (PBL) transduced with these TCRs could recognize multiple HLA-A*11:01+ tumor lines bearing the appropriate KRAS mutations. In a xenograft model of large established tumor, adoptive transfer of these transduced PBLs reactive with an HLA-A*11:01, G12D-mutated pancreatic cell line could significantly reduce its growth in NSG mice (P = 0.002). The success of adoptive transfer of TCR-engineered T cells against melanoma and other cancers supports clinical trials with these T cells that recognize mutated KRAS in patients with a variety of common cancer types. Cancer Immunol Res; 4(3); 204–14. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Building on these results, TCRs targeting KRASG12D and KRASG12V were produced in HLAA11:01 transgenic mice, and peripheral blood lymphocytes were generated retrovirally [107].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [107]
The cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [89]
In the citing paper
“The transduced PBLs could recognize multiple HLA-A*11:01(+) tumor lines bearing the appropriate KRAS mutations.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [606]
In the citing paper
“Adoptive transfer of these transduced PBLs resulted in a significant reduction in tumor growth in a xenograft model by detecting human KRAS-mutant pancreatic cells.606”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [606]
In the citing paper
“In 2016, Wang and co-workers isolated highly reactive T-cell receptors (TCR) to mutated KRAS variants G12V and G12D from murine T cells in immunized HLA-A*11:01 (258) transgenic mice, which were then transduced into peripheral blood lymphocytes (PBLs).”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [606]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationKRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,454
Self-citationJohnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421
Self-citation
Cited by
Sorted by citations
Items 201–240 of 240
Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine
Pinto, C., Bischl, R., Knežević, L., Ahmadi-Erber, S. M., Huang, K. B., Schmidt, S., Steinberger, P., Orlinger, K. K., Lauterbach, H., & Raguz, J. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01034-7 · Cited by 2
Yeni, Y., & Nining, N. (2022) · Turkish computational and theoretical chemistry/Turkish computational and theoretical chemistry : · doi:10.33435/tcandtc.1140158 · Cited by 2
Epitope identification for p53R273C mutant
Zhang, J., Liu, M., Chen, Y., Zhou, Z., Wang, P., Yu, Y., & Jiao, S. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.752 · Cited by 1
Mice with a diverse human T cell receptor repertoire selected on multiple HLA class I molecules
Dhamodaran, A., Chen, X. T., Fellmer, N., Agrawal, D., Danner, E. W., Kühn, R., & Blankenstein, T. J. F. (2025) · Nature Communications · doi:10.1038/s41467-025-61306-y · Cited by 2
Targeted Therapies for Pancreatic Cancer
Lee, M. S., & Pant, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_5 · Cited by 2
Liu, Y., Pan, Y., Ding, H., He, W., Chen, H., Hu, Z., Lu, Z., & Yang, K. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.105002 · Cited by 1
KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers
Yan, M., Liu, K., Xu, J., Liu, Y., Ji, L., & Zhang, S. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02659-w · Cited by 1
Cancer Vaccine in Solid Tumors: Where We Stand
Roy, S., Ghosh, J., & Ghosh, R. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1735439 · Cited by 1
Cheng, X., Jiang, D., Zhang, L. H., Wang, J. H., Li, Y. Z., Zhai, J. H., Yan, B., Zhang, L. L., Xie, X. W., Li, Z., et al. (2022) · PubMed · doi:10.19723/j.issn.1671-167x.2022.05.016 · Cited by 2
Gurung, H. R., Heidersbach, A. J., Darwish, M., Chan, P., Li, J., Beresini, M. H., Zill, O. A., Wallace, A., Tong, A.-J., Hascall, D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.27.513529 · Cited by 1
Kunert, A. (2018) · RePub (Erasmus University Rotterdam)
Glycans as Targets and Mediators of T-Cell Immunotherapy
Wellhausen, N., Aguilar, W., & Posey, A. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00035-3
Ras and Ras Signaling as a Therapeutic Target in Cancer
Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2
Zheng-Lin, B., & O'Reilly, E. M. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_8
Tsokos, G. C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727394204.793570386
Early Drug Development in Pancreatic Cancer
Pant, S., & Surana, R. (2022) · Springer eBooks · doi:10.1007/978-3-031-05724-3_24
The Prospects of Immunotherapy in Pancreatic Cancer
Ying, H., & Yao, W. (2022) · Springer eBooks · doi:10.1007/978-3-031-05724-3_22
Tokatlian, T., Asuelime, G. E., Naradikian, M. S., Mock, J., Daris, M. E., Martin, A. D., Warshaviak, D. T., Kamb, A., & Hamburger, A. E. (2023) · doi:10.1158/2767-9764.c.6550535.v1
Targeting Rat Sarcoma Viral Oncogene Homolog for Treatment of Gastrointestinal Cancers
Robinson, H. R., Davis, S. L., & Lieu, C. H. (2023) · Advances in Oncology · doi:10.1016/j.yao.2023.01.011
Relationship Between Target and Specific Action of Antibody-Drug Conjugates
Lai, J., & Chen, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-5638-6_2
Levin, N., Paria, B. C., Vale, N. R., Yossef, R., Lowery, F. J., Parkhurst, M. R., Yu, Z., Florentin, M., Cafri, G., Gartner, J. J., et al. (2023) · doi:10.1158/1078-0432.23662695.v1
Self-citationLevin, N., Paria, B. C., Vale, N. R., Yossef, R., Lowery, F. J., Parkhurst, M. R., Yu, Z., Florentin, M., Cafri, G., Gartner, J. J., et al. (2023) · doi:10.1158/1078-0432.23662695
Self-citationZhang, M., Wang, X., Wu, J., Wang, Q., Cui, H., Chen, X., Zhao, Z., Liu, S., & Ye, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133781
Self-citationTherapeutic Targeting of KRAS Oncogene in Pancreatic Ductal Adenocarcinoma (PDAC)
Song, J. J. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i1.6375
Chu, T., Zhang, R., Liu, X., Li, L., Li, Y., Niu, Z., Quan, H., Zhao, Y., & Li, Y. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01509-7
Kar, S., Verma, D., Mehrotra, S., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.017
T-Cell Receptor-Engineered T (TCR-T) Cell Therapy: Advancements, Challenges, and Future Perspectives
Koirala, P., Ghimire, D., Mishra, A., & Bhaduri, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-88695-9_9
Girgis, A. A., Huff, A. L., Davis-Marcisak, E. F., Palmer, T., Wang, H., Kagohara, L. T., Montagne, J. M., Lvovs, D., Danilova, L., Favorov, A. V., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1156
Oncogene Mutations: The Shared Antigen Vaccines That Work?
Paredes, R., Haldar, S. D., Pant, S., & O'Reilly, E. M. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-111400 · Cited by 1
An overview of current immunotherapy approaches for treating gastrointestinal cancers
Ramaka, A., Rajan, A., & Somasundaram, A. (2025) · Surgical Oncology Insight · doi:10.1016/j.soi.2025.100191 · Cited by 1
Liang, Z., Guan, F., Wu, B., Chen, W., Tian, Y., Cai, W., & Li, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736294
Schmitt, T. M., Furiya, K., Black, C., Vazquez, A., Sharma, J., Hailemariam, M., Paushter, D. H., Trieu, L., Lam, J. L., Lee, B., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013520
The role of inflammation in the immune evasion of KRas
Homan, E. J., & Bremel, R. D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1831303 · Cited by 1
Emerging concepts, hot topics, and open questions in today’s pancreatic cancer research
Keber, C. U., Schmitt, M., Visekruna, A., Brichkina, A. I., von Strandmann, E. P., Bartsch, J. W., Huber, M., Bauer, U., Gress, T. M., & Lauth, M. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189614
Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsPreprint
Zhang, M., Rausseo, B. N., Jiang, P., Bontekoe, E., Alves, A. M., Slone, J. K., Rinsurongkawong, W., Rinsurongkawong, V., Patel, A., Lewis, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10030408/v1
Pursley, A., Kirmani, U., Chen, A. L., Yu, Z., Hanada, K., Ade, C. M., Chien, C. D., Cha, N., Flegel, W. A., Aplan, P. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.25.754423
Self-citationWu, X., Effenberger, C., Matsushita, Y., Tanaka, H., Ishii, Y., Re, S., Matsumoto, S., Nagayama, S., Nakamura, Y., & Kiyotani, K. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016411
Lv, S., Ma, C., Tang, Z., Zhang, X., Shi, W., Zhang, S., Ni, M., Gu, L., & Chen, B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1969514
George, B., Singh, H., Devoe, C., Chung, V. M., Hosein, P. J., Hendifar, A., Kim, D. W., Valerin, J. B., Bekaii‐Saab, T., Cardin, D. B., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04734-7
Metadata
- Authors
- Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Wang, Qiong J.
- Yang, James C.
- Venue
- Cancer Immunology Research
- Published
- 2016-02-29
- Volume
- 4
- Issue
- 3
- Pages
- 204-214
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC4775432
- OpenAlex
- W2239878160
- Cited by
- 240
- References
- 37
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 27 · 2023: 30 · 2022: 36 · 2021: 29 · 2020: 24 · 2019: 19 · 2018: 11 · 2017: 13 · 2016: 7
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 CA999999)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- KRAS mutation, T cell receptor engineering, neoantigens, HLA-A*11:01, pancreatic cancer, adoptive T cell therapy, xenograft tumor growth, cancer immunotherapy
- MeSH terms
- Amino Acid Sequence, Animals, Humans, Lymph Nodes, Mice, Transgenic, Neoplasm Transplantation, Pancreatic Neoplasms, Receptors, Antigen, T-Cell, Spleen, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Adoptive Transfer, Mutation, Missense, Cell Line, Tumor, HLA-A11 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
